Get the Daily Brief
Latest Biotech News
Guardant expands screening push — buys MetaSight and lifts Shield outlook
Guardant Health acquired MCED startup MetaSight Diagnostics for $59 million upfront plus contingent payments and projected strong growth for its Shield colorectal screening product in 2026....
FDA clears Vanda’s Bysanti — new antipsychotic approval
The FDA approved Vanda Pharmaceuticals’ Bysanti for schizophrenia and for acute manic or mixed episodes in bipolar I disorder. Bysanti is an active metabolite of an existing atypical antipsychotic...
Japan backs two iPSC therapies under conditional pathway
Japan’s regulatory advisory panel recommended conditional, time‑limited endorsements for two induced pluripotent stem cell (iPSC)‑derived therapies: Amchepry (raguneprocel) from Sumitomo...
RNR regulation decoded — structural insights point to new antibacterial targets
New structural and mechanistic work on ribonucleotide reductases (RNRs) and their bacterial regulator NrdR has clarified how bacteria control dNTP synthesis, exposing bacterial‑specific control...
Disorder helps: messy lipid nanoparticles improve RNA delivery
Single‑particle analyses revealed two LNP subpopulations — organized and amorphous — and showed that the disordered, 'messy' nanoparticles release RNA cargo more effectively inside cells....
AI arms race in drug discovery — autonomous 'prompt‑to‑drug' vs closed proprietary models
Insilico Medicine and Eli Lilly published a vision paper outlining an end‑to‑end autonomous 'prompt‑to‑drug' R&D framework that chains generative AI tools into integrated discovery workflows. The...
CAR‑NK tweaks boost tumor killing in preclinical models
Researchers at the Ribeirão Preto Blood Center and the University of São Paulo’s Center for Cell‑Based Therapy reported novel approaches that enhance CAR‑NK efficacy using the NK‑92 cell line. The...
Diagnostics consolidation and new platforms reshape testing market
Danaher agreed to acquire patient monitoring firm Masimo in a roughly $9.9 billion cash deal while Cepheid was selected as one of four CDC collaborators under a rapid‑diagnostics IDIQ aimed at...
Grail’s Galleri misses endpoint — shares plunge
Grail reported that its large NHS-Galleri multicancer early detection (MCED) trial did not meet the primary endpoint of a statistically significant reduction in late-stage (III–IV) cancer...
FDA reverses course: Moderna flu vaccine under review
The FDA reversed a recent refusal-to-file decision and agreed to accept Moderna’s application for review of its mRNA influenza vaccine, mRNA‑1010, after a Type A meeting between the agency and the...
Guardant expands screening play — MetaSight buy and Shield ramp
Guardant Health disclosed an acquisition of early‑cancer detection startup MetaSight Diagnostics and issued guidance expecting material growth in its Shield colorectal‑cancer screening business...
Danaher shells out nearly $10B for Masimo — diagnostics consolidation
Danaher entered a definitive agreement to acquire Masimo Corporation for approximately $9.9 billion ($180 per share), accelerating Danaher’s push into acute‑care monitoring and diagnostics. The...
Japan backs two iPSC therapies under early‑approval pathway
Japan’s regulatory advisory body recommended conditional approvals for two induced pluripotent stem cell (iPSC)‑derived therapies: Amchepry (raguneprocel) from Sumitomo Pharma/Racthera and Reheart...
Ionis halts Alzheimer candidate for Down syndrome
Ionis Pharmaceuticals discontinued development of a candidate intended to prevent Alzheimer’s disease in people with Down syndrome, the company confirmed following reporting by Endpoints. Ionis...
Stanford mucosal vaccine protects mice from diverse respiratory threats
Researchers at Stanford reported a nasal vaccine in Science that produced broad protection in mice against multiple respiratory viruses, bacteria and even allergen challenge. The intranasal...
Cryo‑EM maps CSN5i‑3 binding — orthosteric molecular‑glue revealed
A structural study using cryo‑electron microscopy detailed how CSN5i‑3 binds within the intact COP9 signalosome (CSN) complex, defining its orthosteric molecular‑glue mechanism. The work clarifies...
New structural insights into bacterial DNA synthesis control point to antimicrobial target
Researchers reported structural and mechanistic characterization of NrdR, a bacterial transcriptional regulator that controls ribonucleotide reductase (RNR) expression and thus dNTP supply for DNA...
Grail’s Galleri flops in NHS study: shares tumble
Grail reported that its large NHS-Galleri multicancer early detection (MCED) trial failed to meet the study's primary endpoint, triggering a sharp sell-off in the company's stock. The company...
FDA formalizes one-trial default: NEJM authors set new standard
Top FDA officials signaled a formal policy shift: the agency will now default to accepting a single well-controlled pivotal clinical trial as sufficient evidence for drug approval, supplemented by...
Moderna’s flu vaccine review reverses course: FDA will now review
Moderna secured a last-minute regulatory reprieve: the FDA reversed an initial Refusal to File and will now accept review of the company’s mRNA influenza vaccine, mRNA-1010, after a Type A...